Nowture has entered the capital of Libera Bio, whose patented MPN Technology aims at developing a new paradigm in the treatment of cancer. The technology addresses intracellular targets that have so far been inaccessible to large molecules including full monoclonal antibodies. Libera Bio’s lead compound is a MPN-antiKRAS – the RAS family is associated with 30% of all cancers. Nowture has participated in a round in which it is the lead investor and reserves the right to lead the following capital increases up to an amount of six million euros, explains the group.
Nowture is a comprehensive ecosystem that invests in – and offers a global model of support services for – transformative companies in the life sciences sector.
For more information: